What's Happening?
Daniel Barber, CEO of Aquestive Therapeutics, has emphasized the strategic advantages of onshoring manufacturing operations in the U.S. amidst evolving global dynamics. Aquestive, which operates two facilities in Portage, Indiana, has maintained its manufacturing processes
domestically, citing benefits such as flexibility, intellectual property protection, and compliance management. Barber noted that while the financial gap between domestic and offshore manufacturing has narrowed over the years, geopolitical changes and the complexity of drug production processes have made onshoring more appealing. Despite the challenges of sourcing active pharmaceutical ingredients (APIs) from abroad, Barber advocates for increased domestic API production to mitigate cross-border risks.
Why It's Important?
The shift towards onshoring in the pharmaceutical industry reflects broader economic and geopolitical trends that could significantly impact U.S. manufacturing and employment. By keeping production local, companies like Aquestive can respond more swiftly to client demands and protect their intellectual property. This trend also aligns with national interests in reducing dependency on foreign supply chains, particularly for critical components like APIs. The potential increase in domestic manufacturing could lead to job creation and economic growth, while also addressing national security concerns related to supply chain vulnerabilities.
What's Next?
As the U.S. continues to navigate the complexities of global trade and manufacturing, the focus on onshoring is likely to persist. The pharmaceutical industry may see increased investment in domestic facilities, driven by both government incentives and the need for supply chain resilience. However, the transition will require addressing regulatory challenges and ensuring the availability of technical labor. The ongoing discussion about reshoring API production will be crucial in determining the future landscape of U.S. pharmaceutical manufacturing.
